MBF Therapeutics Showcases Veterinary Oncology Portfolio at Animal Health Investment...

MBF Therapeutics Showcases Veterinary Oncology Portfolio at Animal Health
Investment Forum
Company Presents Plans for Rapid Commercialization of Companion Animal
Therapeutics at Kansas City Meeting

KANSAS CITY, Mo., Sept. 1 /PRNewswire/ -- MBF Therapeutics Inc. (MBFT)
www.mbftherapeutics.com , a development stage veterinary oncology company
headquartered in the metro Philadelphia area, is one of 17 companies selected
to present to investors at the first annual Animal Health Investment Forum
here today. The companion animal cancer care company is developing
innovative, new and humane therapies for the high value veterinary market.

"MBFT is taking advantage of the significant advances in human cancer
treatment by adapting therapies proven safe in human clinical studies for use
in companion animals," said Tom Tillett, MBFT president and CEO. By
in-licensing established, proprietary cancer therapies, MBFT expects to be
able to commercialize its first products within three years, he noted.

The oncology market represents the greatest unmet need in veterinary medicine,
a fast-growing segment estimated at more than $0.5 billion. Today's primary
cancer therapies for dogs and cats are palliative, frequently offering only a
nominal extension of life, often with a significant decrease in life quality.

"That is why MBFT is focusing on a portfolio of therapies that do not merely
delay cancer progression but also extend good quality of life by actually
shrinking or eradicating tumors, products that are effective against
lymphoma, and products that will lower cost per treatment to address this
unmet need," Tillett explained.

About MBF Therapeutics:Ambler, PA-basedMBF Therapeutics is capitalizing on the
lack of effective cancer therapies in the companion animal health arena to
develop novel, proprietary veterinary oncology products. Our strategy focuses
on the acquisition and clinical development of products that will not only be
disruptive to existing markets, but will also create new markets for clinical
therapy. Our portfolio includes targeted gene-based and small molecule
products with well-understood mechanisms of action that specifically disrupt
tumor cell metabolism and/or modulate immune function. For further
information, please visit our Web site, www.mbftherapeutics.com or contact us
at 215-620-3699.

CONTACT:
Christina Pagano
Pagano & Co. PR
+1-212-213-2851
paganopr@aol.com

Lorraine Keller
MBF Therapeutics
+1-215-205-6084
lkeller@mbftherapeutics.com

SOURCE MBF Therapeutics Inc.

Christina Pagano, of Pagano & Co. PR, +1-212-213-2851, paganopr@aol.com, or
Lorraine Keller, of MBF Therapeutics, +1-215-205-6084,
lkeller@mbftherapeutics.com